Noriko Iwaki

TL;DR: TAFRO syndrome is a unique subtype of iMCD that demonstrates characteristic clinicopathological findings and further study to clarify prognosis, pathophysiology, and appropriate treatment is needed.

TL;DR: In conclusion, patients with IgG4-related skin disease had uniform clinicopathology, and lesions were frequently present on the skin of the periauricular, cheek, and mandible regions, and were frequently accompanied by IgG 4-related lymphadenopathy.

TL;DR: The association of these atypical features with well-known multicentric Castleman's disease (MCD), namely, HV-type histology with systemic lymphadenopathy, marked thrombocytopenia even with a high level of interleukin-6, and increased acute inflammatory proteins without hyper-γ-globulinemia, suggests that TAFRO syndrome as presented in this case is a novel entity.

TL;DR: The morphological differences in the pathological findings ofMTX‐LPD may be a factor for spontaneous or non‐spontaneous regression after discontinuation of MTX, and overall survival was not significantly different between DLBCL‐type and CHL‐ type.

TL;DR: Although the follow‐up duration was relatively short, the study met the primary endpoint and tirabrutinib monotherapy is considered to be highly effective for both untreated and relapsed/refractory WM with a manageable safety profile.